BiotechTube

BYM338 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Skeletal Muscle

Conditions

Skeletal Muscle

Trial Timeline

Jan 1, 2012 → Dec 1, 2013

NCT ID
NCT01601600

About BYM338 + Placebo

BYM338 + Placebo is a phase 2 stage product being developed by Novartis for Skeletal Muscle. The current trial status is completed. This product is registered under clinical trial identifier NCT01601600. Target conditions include Skeletal Muscle.

What happened to similar drugs?

1 of 3 similar drugs in Skeletal Muscle were approved

Approved (1) Terminated (0) Active (2)
✅LumiracoxibNovartisApproved
🔄Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
🔄Botulinum toxin type AIpsenPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01868685Phase 2Withdrawn
NCT01601600Phase 2Completed
NCT01423110Phase 2Completed

Competing Products

9 competing products in Skeletal Muscle

See all competitors
ProductCompanyStageHype Score
Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
40
No interventionJohnson & JohnsonPre-clinical
26
HRS-9190Jiangsu Hengrui MedicinePhase 1
29
HRS-9190 for InjectionJiangsu Hengrui MedicinePhase 1
29
ACE-083MerckPhase 1
29
LumiracoxibNovartisApproved
43
Nerve Growth FactorLundbeckPre-clinical
15
Botulinum toxin type AIpsenPhase 3
37
BurosumabUltragenyx PharmaceuticalPhase 1
19